SCHEMBL4152109

SCHEMBL4152109

O=C(Nc1cccnc1)c1ccnc2[nH]c(-c3ccc(N4CCCCC4)cc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.53
MAPT P10636 5/20 0.52
RAB9A P51151 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
ALDH1A1 P00352 3/20 0.52
NPC1 O15118 3/20 0.52
TP53 P04637 2/20 0.52
GFER P55789 1/20 0.52
GSK3A P49840 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.48
MCL1 Q07820 1/20 0.44
AURKA O14965 1/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
KLF5 Q13887 1/20 0.43
ITK Q08881 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152912 0.92 TP53 (0.53) GSK3BRAB9ASMN1; SMN2NPC1TP53
SCHEMBL4160814 0.91 LRRK2 (0.53) GSK3BRAB9ASMN1; SMN2NPC1GSK3A
SCHEMBL8237423 0.89 GSK3B (0.47) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4158991 0.89 GSK3B (0.54) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4145805 0.88 GSK3B (0.55) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4152662 0.87 RAB9A (0.54) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4149998 0.86 RAB9A (0.54) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4149980 0.83 GSK3B (0.58) GSK3BMAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4156450 0.83 GSK3B (0.74) GSK3BALDH1A1MCL1HTTTDP1
SCHEMBL4152711 0.83 MAPK10 (0.54) MAPTRAB9ASMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MAPT 119/4885RAB9A 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.